Westover Capital Advisors LLC Decreases Stake in Vera Therapeutics, Inc. (NASDAQ:VERA)

Westover Capital Advisors LLC cut its stake in shares of Vera Therapeutics, Inc. (NASDAQ:VERA) by 21.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,900 shares of the company’s stock after selling 1,324 shares during the quarter. Westover Capital Advisors LLC’s holdings in Vera Therapeutics were worth $207,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in VERA. Mirae Asset Global Investments Co. Ltd. increased its holdings in Vera Therapeutics by 21.4% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,983 shares of the company’s stock worth $86,000 after buying an additional 350 shares during the period. KBC Group NV increased its stake in shares of Vera Therapeutics by 127.2% in the fourth quarter. KBC Group NV now owns 2,477 shares of the company’s stock worth $105,000 after acquiring an additional 1,387 shares during the period. AlphaCentric Advisors LLC purchased a new position in shares of Vera Therapeutics during the third quarter worth $332,000. Point72 Asia Singapore Pte. Ltd. lifted its position in Vera Therapeutics by 109.4% during the third quarter. Point72 Asia Singapore Pte. Ltd. now owns 9,407 shares of the company’s stock valued at $416,000 after purchasing an additional 4,914 shares during the period. Finally, Intech Investment Management LLC purchased a new stake in Vera Therapeutics in the third quarter valued at $475,000. 99.21% of the stock is owned by institutional investors and hedge funds.

Vera Therapeutics Stock Performance

Shares of NASDAQ:VERA opened at $28.60 on Wednesday. The company has a debt-to-equity ratio of 0.17, a current ratio of 13.76 and a quick ratio of 13.76. Vera Therapeutics, Inc. has a 1 year low of $25.99 and a 1 year high of $51.61. The firm has a market capitalization of $1.81 billion, a PE ratio of -10.96 and a beta of 1.11. The business’s 50 day moving average price is $35.21 and its 200-day moving average price is $40.22.

Vera Therapeutics (NASDAQ:VERA) last issued its earnings results on Wednesday, February 26th. The company reported ($0.72) EPS for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.11. As a group, equities research analysts expect that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have weighed in on VERA shares. JPMorgan Chase & Co. decreased their price objective on Vera Therapeutics from $77.00 to $71.00 and set an “overweight” rating for the company in a report on Tuesday. Wedbush boosted their price target on Vera Therapeutics from $30.00 to $38.00 and gave the company a “neutral” rating in a report on Friday, November 8th. Guggenheim boosted their target price on shares of Vera Therapeutics from $59.00 to $61.00 and gave the company a “buy” rating in a research note on Thursday, February 27th. Wells Fargo & Company started coverage on Vera Therapeutics in a research note on Thursday, November 21st. They issued an “overweight” rating and a $70.00 price target for the company. Finally, The Goldman Sachs Group began coverage on Vera Therapeutics in a research report on Tuesday, January 28th. They set a “buy” rating and a $58.00 price target on the stock. One analyst has rated the stock with a hold rating, six have given a buy rating and three have issued a strong buy rating to the company’s stock. According to MarketBeat, Vera Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $64.67.

Insiders Place Their Bets

In related news, CEO Marshall Fordyce sold 17,500 shares of the stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $46.94, for a total value of $821,450.00. Following the completion of the sale, the chief executive officer now owns 85,942 shares of the company’s stock, valued at approximately $4,034,117.48. This trade represents a 16.92 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold 52,500 shares of company stock valued at $2,305,625 in the last ninety days. 21.70% of the stock is currently owned by corporate insiders.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.